This renders Class I HDAC inhibitors, such as Entinostat, interesting candidates for treatment of metabolic diseases and it highlights the need for better understanding of mechanisms behind the formation of hepatic lipid store droplets. The gene discussed is HDAC9; the disease is metabolic disease.